Idera Pharma gains on new U.S. patent for cancer drug tilsotolimod

Aceragen

28/09/2020 15:52

** Shares of drug developer  IDRA.O  up ~3% at $2.34 
    ** Says it received a new U.S. patent for its cancer drug
tilsotolimod that covers it through September 2037  urn:newsml:reuters.com:*:nGNXKP2mb
    ** New patent and allowed application include claims for
methods of treating colorectal cancer and head and neck cancer
with tilsotolimod 
    ** Stock has risen 28.5% so far this year

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))